Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | DRP-104 + unspecified PD-L1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DRP-104 | DRP 104|DRP104|Sirpiglenastat | Sirpiglenastat (DRP-104) is the prodrug form of glutamine antagonist, which potentially modulates immune response and inhibits tumor growth (J Immunother Cancer. 2019; 7(Suppl 1): 282, Abs nr: P497). | ||
unspecified PD-L1 antibody | Experimental PD-L1 antibody | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|